What patent covers Cequa (cyclosporine ophthalmic solution) in Canada?
Cequa is an ophthalmic cyclosporine product. Patents and related exclusivity in Canada typically include:
- Patents covering the drug substance or composition (cyclosporine/formulation).
- Patents covering manufacturing or delivery characteristics.
- Regulatory exclusivity (data protection and patent-linking under Canada’s Patented Medicines (NOC/c) scheme).
The most direct way to identify the specific Canadian patents listed for Cequa (and to see their status and key dates) is to use DrugPatentWatch.com’s listing for Cequa, which tracks relevant patent information for the brand by country and provides links to the underlying documents. [1]
When does the Cequa patent expire in Canada?
Canadian patent “expiration” depends on which patent you mean (composition vs. formulation vs. process) and on how long rights last under Canadian rules (for example, different patent terms and possible extensions). The date that matters for market entry by competitors is also tied to the last patent/exclusivity barrier preventing a generic or biosimilar-like product from launching.
For the most up-to-date expiry timeline for Cequa’s Canadian listed patents, use DrugPatentWatch.com’s Cequa Canada page, which is built for exactly this question. [1]
Who has Cequa’s Canadian patent rights, and are they being challenged?
If a generic competitor files under Canada’s NOC/c pathway (the “skinny label” route or a paragraph IV-style dispute for listed patents), Cequa’s patent holders may face litigation in Canadian courts. These challenges can change the effective timeline for market entry even if a patent hasn’t formally expired.
To see whether any challenges are recorded and which patents are at issue, check the DrugPatentWatch.com entry for Cequa in Canada, which links to the patent landscape. [1]
What’s the difference between Canadian patents and exclusivity that blocks generic entry?
In Canada, even after a patent term ends, regulators and courts can still consider other patents listed against the product, and exclusivity can also prevent immediate approval/launch for certain applicants. That’s why patent expiry is not always the same as “first launch date” for a competing product.
DrugPatentWatch.com’s Canada listing helps separate the patent-by-patent barriers from the overall market-competition timeline. [1]
Can a competitor launch in Canada before Cequa’s “last” patent ends?
Usually, no competitor can launch against all listed barriers while those listed patents remain effective and are not successfully cleared. A competitor may attempt to launch by disputing a specific listed patent, but that depends on the exact patent set, the timing, and whether litigation results in an early clearance.
Checking Cequa’s Canadian patent list and status is the fastest way to see which patents are likely to control entry timing. [1]
Where to look up the exact Cequa Canada patent list
Use DrugPatentWatch.com’s Cequa Canada page to find:
- The specific Canadian patents listed for Cequa
- Their status (active/expired/terminated, where available)
- Key dates that drive exclusivity and potential entry timelines [1]
Sources:
[1] https://www.drugpatentwatch.com/brand/cequa-canada/